PeptiDream

Developer of radiopharmaceuticals intended to offer treatment of cancer. The company engages in the research and development of therapeutic and diagnostic drugs for cancer using 64Cu which is a radioisotope of copper, enabling doctors to provide cancer treatments to the patients.

Developer of radiopharmaceuticals intended to offer treatment of cancer. The company engages in the research and development of therapeutic and diagnostic drugs for cancer using 64Cu which is a radioisotope of copper, enabling doctors to provide cancer treatments to the patients.

Kleo Pharmaceuticals, Inc. is a biotechnology company based in New Haven, Connecticut, focused on developing immunotherapies that harness small molecules to activate the immune system against cancer. Founded in 2015, Kleo is advancing two main types of compounds: Antibody Recruiting Molecules (ARMs) and Synthetic Antibody Mimics (SyAMs). These compounds are designed to be non-immunogenic, highly stable, and lower in molecular weight, allowing for faster and more cost-effective production. Kleo's technology aims to provide safer and more effective treatment options for cancer and infectious diseases, enabling medical practitioners to initiate tumor treatments promptly, thereby increasing the chances of successful outcomes. As of January 2021, Kleo operates as a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.

Alivexis is a preclinical stage drug discovery company based in Tokyo, specializing in the rapid design and generation of small molecule clinical candidates aimed at addressing high-value disease targets. The company leverages advanced computational drug discovery techniques and unique biological insights to accelerate the development of new medicines. Its international team consists of experts in drug design and disease biology, drawing on extensive research and development experience from global pharmaceutical and biotechnology firms. Alivexis's platform is designed to enhance biotechnological research, ultimately enabling healthcare professionals to deliver effective treatments to patients with unmet medical needs.

PeptiStar Inc., founded in 2017 and headquartered in Osaka, Japan, specializes in the development and manufacturing of peptide medicines. As a Contract Development and Manufacturing Organization (CDMO), PeptiStar offers a range of services for peptide active pharmaceutical ingredients (APIs), including traditional and advanced forms such as macrocyclic and stapled peptides that incorporate non-natural amino acids. The company focuses on innovative manufacturing technologies to enhance the efficiency and effectiveness of peptide therapeutics, thereby supporting the pharmaceutical industry in accelerating drug development. Through its commitment to open innovation, PeptiStar aims to deliver high value-added services to its clients, contributing significantly to advancements in peptide medicine.

PharmaDesign is a genomic drug discovery venture company.